AAREYDRUGS94.99

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹270 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity3.532.912.642.64
Return on Assets1.541.691.331.33
Return on Capital Employed2.010.222.842.84
Return on Invested Capital1.480.121.591.80
Margins
EBITDA Margin1.130.481.521.64
Operating Margin0.700.060.910.91
Incremental Operating Margin-3.12-239.65
Pretax Margin1.351.291.151.01
Net Income Margin1.180.850.841.18
FCF Margin1.992.04-0.48-0.48
Additional
Effective Tax Rate12.3434.0526.72-16.22
Sustainable Growth Rate3.532.912.642.64
Incremental Operating Margin %-3.12-239.651.28
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.